Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Jun;97(2):383–390. doi: 10.1111/j.1476-5381.1989.tb11965.x

Reduction of cephalic arteriovenous shunting by ergotamine is not mediated by 5-HT1-like or 5-HT2 receptors.

A H Bom 1, J P Heiligers 1, P R Saxena 1, P D Verdouw 1
PMCID: PMC1854530  PMID: 2758221

Abstract

1. The potent, antimigraine drug ergotamine has affinity for both 5-HT1 and 5-HT2 binding sites and constricts arteriovenous anastomoses. Since 5-HT also constricts arteriovenous anastomoses (mainly via 5-HT1-like receptors), this study investigates the involvement of 5-HT receptors in the ergotamine-induced reduction of arteriovenous shunting in the carotid circulation of the cat and pig. 2. In the cat, ergotamine (3, 10 and 30 micrograms kg-1, i.v.) reduced carotid blood flow, predominantly by a reduction in arteriovenous anastomotic blood flow. Pretreatment with ketanserin (0.5 mg kg-1, i.v.) or methiothepin (1 mg kg-1, i.v.) did not antagonize the effects of ergotamine. 3. In the pig, ergotamine (2.5, 5, 10 and 20 micrograms kg-1, i.v.) also reduced carotid blood flow and arteriovenous shunting, which was not affected by pretreatment with methiothepin (1 mg kg-1, i.v.). 4. These results suggest that the reduction by ergotamine in the shunting of carotid arterial blood via cephalic arteriovenous anastomoses is not mediated by 5-HT1-like or 5-HT2 receptors.

Full text

PDF
383

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anggard A. Capillary and shunt blood flow in the nasal mucosa of the cat. Acta Otolaryngol. 1974 Nov-Dec;78(5-6):418–422. [PubMed] [Google Scholar]
  2. Bell C., Lang W. J. Evidence for dopaminergic vasodilator innervation of the canine paw pad. Br J Pharmacol. 1979 Nov;67(3):337–343. doi: 10.1111/j.1476-5381.1979.tb08685.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bell C., Lang W. J., Laska F. Dopamine-containing axons supplying the arterio-venous anastomoses of the canine paw pad. J Neurochem. 1978 Nov;31(5):1329–1333. doi: 10.1111/j.1471-4159.1978.tb06259.x. [DOI] [PubMed] [Google Scholar]
  4. Bom A. H., Duncker D. J., Saxena P. R., Verdouw P. D. 5-Hydroxytryptamine-induced tachycardia in the pig: possible involvement of a new type of 5-hydroxytryptamine receptor. Br J Pharmacol. 1988 Mar;93(3):663–671. doi: 10.1111/j.1476-5381.1988.tb10324.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bradley P. B., Engel G., Feniuk W., Fozard J. R., Humphrey P. P., Middlemiss D. N., Mylecharane E. J., Richardson B. P., Saxena P. R. Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology. 1986 Jun;25(6):563–576. doi: 10.1016/0028-3908(86)90207-8. [DOI] [PubMed] [Google Scholar]
  6. Connor H. E., Feniuk W., Humphrey P. P., Perren M. J. 5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats. Br J Pharmacol. 1986 Feb;87(2):417–426. doi: 10.1111/j.1476-5381.1986.tb10832.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. GILLILAN L. A., MARKESBERY W. R. ARTERIOVENOUS SHUNTS IN THE BLOOD SUPPLY TO THE BRAINS OF SOME COMMON LABORATORY ANIMALS--WITH SPECIAL ATTENTION TO THE RETE MIRABILE CONJUGATUM IN THE CAT. J Comp Neurol. 1963 Dec;121:305–311. doi: 10.1002/cne.901210302. [DOI] [PubMed] [Google Scholar]
  8. Humphrey P. P., Feniuk W., Perren M. J., Connor H. E., Oxford A. W., Coates L. H., Butina D. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol. 1988 Aug;94(4):1123–1132. doi: 10.1111/j.1476-5381.1988.tb11630.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Johnston B. M., Saxena P. R. The effect of ergotamine on tissue blood flow and the arteriovenous shunting of radioactive microspheres in the head. Br J Pharmacol. 1978 Jul;63(3):541–549. doi: 10.1111/j.1476-5381.1978.tb07810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Kaumann A. J. Two classes of myocardial 5-hydroxytryptamine receptors that are neither 5-HT1 nor 5-HT2. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S76–S78. doi: 10.1097/00005344-198500077-00022. [DOI] [PubMed] [Google Scholar]
  11. Krönert H., Wurster R. D., Pierau F. K., Pleschka K. Vasodilatory response of arteriovenous anastomoses to local cold stimuli in the dog's tongue. Pflugers Arch. 1980 Oct;388(1):17–19. doi: 10.1007/BF00582623. [DOI] [PubMed] [Google Scholar]
  12. Puzich R., Girke W., Heidrich H., Rischke M. Dopplersonographische Untersuchungen der extrakraniellen Hirngefässe bei Migräne-Patienten nach Gabe von Ergotamintartrat. Dtsch Med Wochenschr. 1983 Mar 25;108(12):457–461. doi: 10.1055/s-2008-1069578. [DOI] [PubMed] [Google Scholar]
  13. ROWBOTHAM G. F., LITTLE E. NEW CONCEPTS ON THE AETIOLOGY AND VASCULARIZATION OF MENINGIOMATA; THE MECHANISM OF MIGRAINE; THE CHEMICAL PROCESSES OF THE CEREBROSPINAL FLUID; AND THE FORMATION OF COLLECTIONS OF BLOOD OR FLUID IN THE SUBDURAL SPACE. Br J Surg. 1965 Jan;52:21–24. doi: 10.1002/bjs.1800520105. [DOI] [PubMed] [Google Scholar]
  14. Roquebert J., Grenié B. Alpha 2-adrenergic agonist and alpha 1-adrenergic antagonist activity of ergotamine and dihydroergotamine in rats. Arch Int Pharmacodyn Ther. 1986 Nov;284(1):30–37. [PubMed] [Google Scholar]
  15. Saxena P. R. Arteriovenous shunting and migraine. Res Clin Stud Headache. 1978;6:89–102. [PubMed] [Google Scholar]
  16. Saxena P. R., Cairo-Rawlins W. I. Presynaptic inhibition by ergotamine of the responses to cardioaccelerator nerve stimulations in the cat. Eur J Pharmacol. 1979 Oct 1;58(3):305–312. doi: 10.1016/0014-2999(79)90479-5. [DOI] [PubMed] [Google Scholar]
  17. Saxena P. R., Duncker D. J., Bom A. H., Heiligers J., Verdouw P. D. Effects of MDL 72222 and methiothepin on carotid vascular responses to 5-hydroxytryptamine in the pig: evidence for the presence of "5-hydroxytryptamine1-like" receptors. Naunyn Schmiedebergs Arch Pharmacol. 1986 Jul;333(3):198–204. doi: 10.1007/BF00512930. [DOI] [PubMed] [Google Scholar]
  18. Saxena P. R., Koedam N. A., Heiligers J., Hof R. P. Ergotamine-induced constriction of cranial arteriovenous anastomoses in dogs pretreated with phentolamine and pizotifen. Cephalalgia. 1983 Jun;3(2):71–81. doi: 10.1046/j.1468-2982.1983.0302071.x. [DOI] [PubMed] [Google Scholar]
  19. Saxena P. R., Lawang A. A comparison of cardiovascular and smooth muscle effects of 5-hydroxytryptamine and 5-carboxamidotryptamine, a selective agonist of 5-HT1 receptors. Arch Int Pharmacodyn Ther. 1985 Oct;277(2):235–252. [PubMed] [Google Scholar]
  20. Saxena P. R., Mylecharane E. J., Heiligers J. Analysis of the heart rate effects of 5-hydroxytryptamine in the cat; mediation of tachycardia by 5-HT1-like receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985 Aug;330(2):121–129. doi: 10.1007/BF00499904. [DOI] [PubMed] [Google Scholar]
  21. Saxena P. R., Schamhardt H. C., Forsyth R. P., Hoeve J. Computer programs for the radioactive microsphere technique. Determination of regional blood flows and other haemodynamic variables in different experimental circumstances. Comput Programs Biomed. 1980 Dec;12(2-3):63–84. doi: 10.1016/0010-468x(80)90053-7. [DOI] [PubMed] [Google Scholar]
  22. Saxena P. R., Verdouw P. D. 5-Carboxamide tryptamine, a compound with high affinity for 5-hydroxytryptamine1 binding sites, dilates arterioles and constricts arteriovenous anastomoses. Br J Pharmacol. 1985 Feb;84(2):533–544. doi: 10.1111/j.1476-5381.1985.tb12938.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Saxena P. R., Verdouw P. D. Redistribution by 5-hydroxytryptamine of carotid arterial blood at the expense of arteriovenous anastomotic blood flow. J Physiol. 1982 Nov;332:501–520. doi: 10.1113/jphysiol.1982.sp014427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Saxena P. R., Verdouw P. D. Tissue blood flow and localization of arteriovenous anastomoses in pigs with microspheres of four different sizes. Pflugers Arch. 1985 Feb;403(2):128–135. doi: 10.1007/BF00584089. [DOI] [PubMed] [Google Scholar]
  25. Saxena P. R., de Vlaam-Schluter G. M. Role of some biogenic substances in migraine and relevant mechanism in antimigraine action of ergotamine--studies in an experimental model for migraine. Headache. 1974 Jan;13(4):142–163. doi: 10.1111/j.1526-4610.1974.hed1304142.x. [DOI] [PubMed] [Google Scholar]
  26. Schamhardt H. C., Verdouw P. D., van der Hoek T. M., Saxena P. R. Regional myocardial perfusion and wall thickness and arteriovenous shunting after ergotamine administration to pigs with a fixed coronary stenosis. J Cardiovasc Pharmacol. 1979 Nov-Dec;1(6):673–686. doi: 10.1097/00005344-197911000-00008. [DOI] [PubMed] [Google Scholar]
  27. Spira P. J., Mylecharane E. J., Lance J. W. The effects of humoral agents and antimigraine drugs on the cranial circulation of the monkey. Res Clin Stud Headache. 1976;4:37–75. [PubMed] [Google Scholar]
  28. Spira P. J., Mylecharane E. J., Misbach J., Duckworth J. W., Lance J. W. Internal and external carotid vascular responses to vasoactive agents in the monkey. Neurology. 1978 Feb;28(2):162–173. doi: 10.1212/wnl.28.2.162. [DOI] [PubMed] [Google Scholar]
  29. Verdouw P. D., Jennewein H. M., Heiligers J., Duncker D. J., Saxena P. R. Redistribution of carotid artery blood flow by 5-HT: effects of the 5-HT2 receptor antagonists ketanserin and Wal 1307. Eur J Pharmacol. 1984 Jul 20;102(3-4):499–509. doi: 10.1016/0014-2999(84)90571-5. [DOI] [PubMed] [Google Scholar]
  30. Verdouw P. D., Jennewein H. M., Mierau J., Saxena P. R. N-(3-acetylaminophenyl)piperazine hydrochloride (BEA 1654), a putative 5-HT1 agonist, causes constriction of arteriovenous anastomoses and dilatation of arterioles. Eur J Pharmacol. 1985 Jan 8;107(3):337–346. doi: 10.1016/0014-2999(85)90259-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES